Spaulding-Harvard Model System: Effects of Transcranial Direct Current Stimulation (tDCS) on Chronic Pain in Spinal Cord Injury
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
The purpose of this study is to see the effects of transcranial direct current stimulation (tDCS) on the pain associated with spinal cord injury. This study is part of the Spaulding-Harvard Model System. The investigators hypothesize that there will be a decrease in pain levels with active stimulation, when compared to sham stimulation, using a 3 week stimulation schedule- 1 week of stimulation (5 consecutive days) followed by 2 weeks of stimulation (10 consecutive days) after a 3-month follow up visit. The subject will also have follow ups at 2, 4 and 8 weeks after the second course of stimulation.
If a subject receives sham during the experiment, he/she may enroll in an open-label portion of the study and receive 10 days of active stimulation.
Condition | Intervention | Phase |
---|---|---|
Spinal Cord Injury Chronic Pain Neuropathic Pain |
Device: Transcranial direct current stimulation (tDCS) |
Phase 2 |
Study Type: | Interventional |
Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Outcomes Assessor) Primary Purpose: Treatment |
Official Title: | Spaulding-Harvard Spinal Cord Injury (SH-SCI) Study: Effects of tDCS on Chronic Pain in Spinal Cord Injury. |
- Change in Pain Scale [ Time Frame: Measured for approximately 6 months ] [ Designated as safety issue: No ]Determine whether anodal transcranial direct current stimulation is effective in reducing pain in subjects with chronic sublesional neuropathic pain due to spinal cord injury, as measured by changes in the Brief Pain Inventory (BPI) from baseline to follow-up (up to 2 months after the final stimulation session).
- Changes in Quality of Life Scale [ Time Frame: Measured for approximately 6 months ] [ Designated as safety issue: No ]Determine whether anodal transcranial direct current stimulation is effective in increasing quality of life in subjects with chronic neuropathic sublesional pain due to spinal cord injury, as measured by changes in the Satisfaction with Life Scale (SWLS), from baseline to follow-up (up to 2 months after the final stimulation session).
- Changes in Mood Scale [ Time Frame: Measured for approximately 6 months ] [ Designated as safety issue: No ]Determine whether anodal transcranial direct current stimulation is effective in improving mood in subjects with chronic neuropathic sublesional pain due to spinal cord injury, as measured by changes in the Patient Health Questionnaire-9 (PHQ9), from baseline to follow-up (up to 2 months after the final stimulation session).
Estimated Enrollment: | 120 |
Study Start Date: | December 2011 |
Estimated Primary Completion Date: | December 2013 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
Experimental: Active tDCS
Subjects will undergo 20 minutes active tDCS.
|
Device: Transcranial direct current stimulation (tDCS)
Subjects will undergo 15 sessions of tDCS stimulation (either active or sham), 1x per day at 20 minutes per session.
Other Names:
|
Sham Comparator: Sham tDCS
Subjects will undergo 20 minutes of sham stimulation.
|
Device: Transcranial direct current stimulation (tDCS)
Subjects will undergo 15 sessions of tDCS stimulation (either active or sham), 1x per day at 20 minutes per session.
Other Names:
|
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Over 18 years of age
- History of moderate to severe sublesional pain
Exclusion Criteria:
- Active alcohol or drug dependence, as self-reported
- A history of bipolar disorder or psychosis, as self-reported
- Inability to travel to the study site,
- Current use of any of the following anti-epileptic medications or dopaminergic medications known to reduce or inhibit the benefits of tDCS treatment [44]: carbamazepine, oxcarbazepine, phenytoin, ropinirole (Requip), pramipexole (Mirapex), and cabergoline (Dostinex),
- The following contradictions to tDCS: implanted metal plates in the head, or deep brain stimulator (spinal cord implants, including baclofen pumps, are not a contraindication as cranial currents do not reach the spinal cord [21]).
- Pregnancy at time of enrollment
Contact: Felipe Fregni, MD PhD MPH | 617-573-2326 | ffregni@partners.org |
Contact: Kayleen M Weaver, BA | 617-573-2196 | kmweaver@partners.org |
United States, Massachusetts | |
Spaulding Rehabilitation Hospital | Recruiting |
Boston, Massachusetts, United States, 02114 |
Principal Investigator: | Felipe Fregni, MD PHD MPH | Spaulding Rehabilitation Hospital |
Additional Information:
No publications provided
Responsible Party: | Felipe Fregni, Associate Professor, Spaulding Rehabilitation Hospital |
ClinicalTrials.gov Identifier: | NCT01599767 History of Changes |
Other Study ID Numbers: | 2011-p-002353 |
Study First Received: | February 8, 2012 |
Last Updated: | July 25, 2012 |
Health Authority: | United States: Institutional Review Board |
Keywords provided by Spaulding Rehabilitation Hospital:
transcranial stimulation direct current |
Additional relevant MeSH terms:
Neuralgia Spinal Cord Injuries Pain Neurologic Manifestations Nervous System Diseases Peripheral Nervous System Diseases |
Neuromuscular Diseases Signs and Symptoms Spinal Cord Diseases Central Nervous System Diseases Trauma, Nervous System Wounds and Injuries |
ClinicalTrials.gov processed this record on October 17, 2012